| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ln Vivo |
A possible endogenous class II metabotropic glutamate receptor agonist that influences thalamic sensory transmission is xanthurenic acid. During iontophoresis and intravenous injection, xanthuric acid (XA) causes sensory suppression. Like other group II mGlu receptor agonists, XA also lessens the suppression caused by physiological sensory input in the thalamic reticular nucleus VB. Furthermore, xanthine acid is thought to be the first possible endogenous mGlu receptor allosteric agonist. Xanthophoric acid, a potential endotoxin that represents both the kynurenine metabolic pathway and class II receptors, is important for studying antipsychotics because these two pathways are closely linked to the pathophysiology of schizophrenia [1]. The combination of these two pathways represents a novel class II receptor ligand.
|
|---|---|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Xanthurenic acid has known human metabolites that include Xanthurenic acid 8-O-sulfate. |
| References | |
| Additional Infomation |
Xanthurenic acid is a quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by hydroxy groups at C-4 and C-8. It has a role as a metabotropic glutamate receptor agonist, an iron chelator, a vesicular glutamate transport inhibitor and an animal metabolite. It is a quinolinemonocarboxylic acid and a dihydroxyquinoline. It is a conjugate acid of a xanthurenate.
Xanthurenic acid has been reported in Charybdis japonica, Procambarus clarkii, and other organisms with data available. Xanthurenic acid is a metabolite found in or produced by Saccharomyces cerevisiae. |
| Molecular Formula |
C10H7NO4
|
|---|---|
| Molecular Weight |
205.1669
|
| Exact Mass |
205.037
|
| CAS # |
59-00-7
|
| Related CAS # |
Xanthurenic acid-d4;1329611-28-0
|
| PubChem CID |
5699
|
| Appearance |
Light yellow to brown solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
514.4±50.0 °C at 760 mmHg
|
| Melting Point |
297-298 °C (dec.)(lit.)
|
| Flash Point |
264.9±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.779
|
| LogP |
2.64
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
336
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FBZONXHGGPHHIY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H7NO4/c12-7-3-1-2-5-8(13)4-6(10(14)15)11-9(5)7/h1-4,12H,(H,11,13)(H,14,15)
|
| Chemical Name |
8-hydroxy-4-oxo-1H-quinoline-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~8.93 mg/mL (~43.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 20 mg/mL (97.48 mM) in 50% PEG300 +50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8740 mL | 24.3700 mL | 48.7401 mL | |
| 5 mM | 0.9748 mL | 4.8740 mL | 9.7480 mL | |
| 10 mM | 0.4874 mL | 2.4370 mL | 4.8740 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
